Development of Injectable Thermosensitive Nanocomposite Hydrogel for Ratiometric Drug Delivery to Treat Drug Resistant Chondrosarcoma In Vivo
Abstract
Chondrosarcoma(CS), a prevalent primary malignant bone tumor, frequently exhibits chemotherapy resistance attributed to upregulated anti‐apoptosis pathways such as the Bcl‐2 family. In this manuscript, a new strategy is presented to augment chemosensitivity and mitigate systemic toxicity by harnessing a nano‐enabled drug delivery hydrogel platform. The platform utilizes “PLGA‐PEG‐PLGA”, an amphiphilic triblock copolymer combining hydrophilic polyethylene glycol (PEG) and hydrophobic polylactide glycolide (PLGA) blocks, renowned for its properties conducive to crafting a biodegradable, temperature‐sensitive hydrogel. This platform is tailored to encapsulate a ratiometrically designed dual‐loaded liposomes containing a first‐line chemo option for CS, Doxorubicin (Dox), plus a calculated amount of small molecule inhibitor for anti‐apoptotic Bcl‐2 pathway, ABT‐737. In vitro and in vivo evaluations demonstrate successful Bcl‐2 suppression, resulting in the restoration of Dox sensitivity, evident through impeded tumor growth and amplified necrosis rates at the tumor site. This delivery system showcases remarkable thermal responsiveness, injectability, and biodegradability, all finely aligned with the clinical demands of CS treatment. Collectively, this study introduces a transformative avenue for tackling drug resistance in CS chemotherapy, offering significant clinical potential.Keywords
Funding Information
- National Key Research and Development Program of China (2022YFA1207300)
- National Natural Science Foundation of China (32271452)
- Beijing Institute of Technology Research Fund Program for Young Scholars (1870011182124)
- Chinese Academy of Sciences (XDB36000000)
This publication has 27 references indexed in Scilit:
- Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel‐Mediated Reprogramming of Cancer‐Associated Fibroblasts in OsteosarcomaAdvanced Materials, 2023
- Preparation, characterization, and Co-delivery of cisplatin and doxorubicin-loaded liposomes to enhance anticancer ActivitiesHeliyon, 2023
- Boosting Glioblastoma Therapy with Targeted Pyroptosis InductionSmall, 2023
- A Tumor Microenvironments‐Adapted Polypeptide Hydrogel/Nanogel Composite Boosts Antitumor Molecularly Targeted Inhibition and ImmunoactivationAdvanced Materials, 2022
- Injectable Immunotherapeutic Thermogel for Enhanced Immunotherapy Post Tumor Radiofrequency AblationSmall, 2021
- Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicityBiomedicine & Pharmacotherapy, 2020
- Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targetsCritical Reviews in Oncology/Hematology, 2018
- Insights into composition/structure/function relationships of Doxil® gained from “high-sensitivity” differential scanning calorimetryEuropean Journal of Pharmaceutics and Biopharmaceutics, 2016
- Doxil® — The first FDA-approved nano-drug: Lessons learnedJournal of Controlled Release, 2012
- Molecular profiling of human chondrosarcomas for matrix production and cancer markersInternational Journal of Cancer, 2002